Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Gains FDA Approval for DUPLEX Delivery of Piperacillin Combo
Details : Piperacillin, a penicillin-class antibacterial, and Tazobactam, a beta-lactamase inhibitor, in the DUPLEX Drug Delivery System and Sodium Chloride, indicated for Intra-abdominal infections.
Product Name : Piperacillin and Tazobactam for Injection
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 09, 2025
Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Baxter Launches Zosyn Premix in US
Details : Zosyn is a combination of piperacillin sodium, which exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria and tazobactam sodium having activity against bacteria due to its reduced affinity to penicil...
Product Name : Zosyn
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 04, 2023
Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization
Deal Size : Inapplicable
Deal Type : Inapplicable
PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 02, 2022
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Rabin Medical Center | University of Modena and Reggio Emilia | Tel Aviv Medical Center | Meir Medical Center | Soroka University Medical Center | The Chaim Sheba Medical Center | McGill University Health Centre Research Institute | Jewish General Hospita
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 14, 2018
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Rabin Medical Center | University of Modena and Reggio Emilia | Tel Aviv Medical Center | Meir Medical Center | Soroka University Medical Center | The Chaim Sheba Medical Center | McGill University Health Centre Research Institute | Jewish General Hospita
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 14, 2016
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 29, 2016
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 22, 2013
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 03, 2013
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable